FDA Says Ongoing CardiAMP HF II Trial May Support Approval
BCDA sits 46% above its 52-week low of $0.75 on light trading volume (0.4× avg).
Summary
BioCardia announced that the FDA has agreed the ongoing CardiAMP HF II trial may be sufficient to support approval of its autologous cell therapy for heart failure. This is a meaningful regulatory de-risking event for a company with a market cap around $16 million. The trial is active, and the company will present a poster at HFSA 2026 (Oct 9-12), which may increase visibility. The news follows a series of regulatory milestones, including the Helix De Novo pre-submission and Nasdaq compliance regained. The key remaining question is whether the trial data will be positive enough to support an actual filing.
At the time of this announcement, BCDA was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16M. The 52-week trading range was $0.75 to $1.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.